Photo credit: College of Veterinary Medicine
A trial led by Dr. Tim Fan at Illinois will evaluate safety and effectiveness of cANK-101 in dogs with oral malignant melanoma. This canine drug was developed by Ankyra Therapeutics, a Boston-based biotech company, using the company’s novel anchored immunotherapy platform. The platform allows retention of immune-oncology drugs in the tumor microenvironment for several weeks, which promotes local immune-mediated tumor regression while limiting systemic toxicity.
“Dogs with melanoma have few effective treatment options,” said Dr. Fan. “By including pet dogs with naturally occurring melanoma, our trial will evaluate this new technology in a highly relevant and immune-competent patient population.”